09 Sep COVID has opened up potentially lucrative opportunities for these Aussie microcaps
Atomo is mentioned in this Stockhead article as one of the Aussie companies involved in the efforts against COVID-19. Read the full article > ...
01 Sep Aussie biotechs join crusade for COVID-19 cure
An article by Stockhead talks about our FY20 results and our COVID-19 antibody tests. Read the full article > ...
31 Aug Atomo Diagnostics’ (ASX:AT1) revenue soars 900pc amid COVID-19 demand
Medical diagnostics company Atomo Diagnostics (AT1) has seen its revenue jump nearly 900 per cent over FY20 as demand for COVID-19 antibody tests skyrockets. Read the full article > ...
31 Aug The world’s best test
An interview with Atomo MD, John Kelly on our FY20 results and strong uplift in revenues. Watch the full interview > ...
11 Aug Biotech Dispatch: TGA approval for Atomo Diagnostics’ COVID-19 diagnostic
Atomo Diagnostics (ASX: AT1) has announced that the TGA has approved its rapid SARS-CoV-2 antibody blood test for use by medical professionals in Australia. Read the full article > ...
10 Aug AFR: Atomo surges 16pc after COVID test gets TGA approval
The healthcare community and broader market initially misunderstood the role of Atomo Diagnostic's COVID-19 antibody test, with CEO John Kelly saying it is designed to be used in conjunction with the gold-standard molecular polymerase chain reaction (PCR) swabs, not as a replacement. Read the full article >...
10 Aug Ausbiz: The Aussie COVID test that takes 15 minutes
MD and CEO discusses TGA approval for our COVID-19 antibody test in this video interview. Read the full article > ...
10 Aug BioWorld: TGA approves Atomo Diagnostics’ rapid COVID-19 antibody test
As the state of Victoria in Australia records its deadliest day since the COVID-19 pandemic began, reporting 17 deaths and 394 new cases, Atomo Diagnostics Ltd.’s new COVID-19 antibody test could ease pressure on health care systems. Read the full article >...
05 Aug CNBC: Covid testing to support future rollout of vaccine: Atomo Diagnostics
In this interview, CEO John Kelly talks about how COVID-19 antibody testing will be important to verify any future vaccine for the virus. Watch the interview > ...
03 Aug BioSpectrum Asia: Atomo Diagnostics collaborates with Access Bio for rapid COVID-19 testing
An article in BioSpectrum Asia on Atomo’s agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
30 Jul Stockhead: COVID-19 testing will last for ‘several years not several months’
In this Stockhead article, CEO, John Kelly discusses why COVID-19 testing will continue for years not months, the development of a vaccine and how Atomo is focused on growing its non-COVID related businesses. Read the full article > ...
28 Jul BioSpace: Atomo Diagnostics and Access Bio partner to expand access to COVID-19 blood-based rapid testing in North America
An article in BioSpace on Atomo’s agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
28 Jul Small Caps: Atomo Diagnostics partners with US biotech for global marketing of COVID-19 rapid test kits
This article in Small Caps article talks about the agreement with US-based Access Bio Inc. for COVID-19 antibody testing in North America. Read the full article > ...
13 Jul The Scientist: How the Pharma Industry Pulled Off the Pivot to COVID-19
Atomo CEO, John Kelly talks about why Atomo developed a rapid diagnostic test for COVID-19. Read the full article > ...
23 Jun ASX: Get to know ASX’s new public company: Atomo Diagnostics Limited (ASX: AT1)
Managing Director and CEO, John Kelly talks to the ASX about the inspiration behind Atomo, listing on the ASX during COVID-19 and why having the right advisors is crucial when you IPO. Watch the video and read the full interview here > ...
05 Jun Ausbiz: Atomo’s new deal means regional production is ramping up just as the recession hits
Managing Director and CEO, John Kelly talks to Ausbiz about Atomo’s expanded partnership with NG Biotech and securing exclusive rights to market and distribute the COVID-19 antibody test for Australia, NZ and parts of SE Asia. Watch the interview here > ...
04 Jun ASX Announcement: Atomo and NG Biotech expand COVID-19 partnership:
Atomo secures exclusive rights for Australia, New Zealand and South East Asia¹ SYDNEY Australia, Thursday, 4 June 2020 – Atomo Diagnostics Limited (ASX: AT1) (Atomo) is pleased to announce it has expanded its existing COVID-19 rapid test partnership with NG Biotech, SAS (NG Biotech), which was...
10 May Stockhead – Dr Boreham’s Crucible: A simpler device gives Atomo the upper hand in blood-based diagnostics
Stockhead’s Tim Boreham discusses Atomo’s background and history and the benefits of its rapid blood test devices for a range of conditions including COVID-19. Read the full article > ...
08 May Stockhead – ScoPo’s health powerplays: How to invest in COVID-19
In an article for Stockhead, Morgans senior analyst Scott Power discusses how Atomo’s rapid test for COVID-19 enabled it to list on the ASX in April. Read the full article > ...
30 Apr Founder and CEO John Kelly interviewed by Peter Switzer
Atomo CEO, John Kelly was interviewed by Peter Switzer on Switzer TV, talking about what makes Atomo’s devices unique, how they can be used to test for COVID-19 and the company’s upcoming key milestones. [embed]https://www.youtube.com/watch?v=XpLiQ6Ujq0c[/embed]...
23 Apr Bloomberg: Biotech Listings Help Prop Up Anemic U.S. IPO Market
An article in Bloomberg talks about Atomo’s rapid share price rise after its ASX listing in a broader piece on US IPOs amid COVID-19. Read the full article > ...
18 Apr Kalkine Media: Atomo Diagnostics – The Shining IPO on ASX Amid COVID 19?
An article on the Kalkine Media website discusses Atomo’s ASX listing, its integrated rapid diagnostic test devices and agreement with NG Biotech for the supply of devices for the rapid blood-based testing of antibodies produced in response to COVID 19. Read the full article > ...
17 Apr WSJ.com: Rapid Coronavirus Test Device Maker’s Shares Soar in IPO
An article in WSJ.com looks at Atomo’s strong ASX debut and how its device could produce blood-test results in 15 minutes for COVID-19 testing. Read the full article > ...
17 Apr The Australian: Coronavirus testing biotech Atomo Diagnostics spikes on ASX debut
An article by Damon Kitney in The Australian discusses how Atomo sharesclosed on their first day of trading on the Australian Securities Exchange at almost double their issue price as investors backed the rollout of its COVID-19 rapid testing equipment. Read the full article > ...
17 Apr Biotech Daily: Atomo IPO Opens Up 95% With 1m Covid-19 Antibody Test Orders
A feature in Biotech Daily talks about Atomo’s successful listing and the strong interest in the use of its integrated rapid test device for the testing of COVID-19 antibodies. Read the full article > ...
16 Apr MEDIA RELEASE: Atomo Diagnostics to list on ASX after successful IPO and virtual bell ringing ceremony
SYDNEY Australia 16 April 2020– Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares in Australian rapid blood test company Atomo Diagnostics Limited (Atomo) will commence on the Australian Securities Exchange (ASX) today under the ticker code...
16 Apr AAP: COVID-19 testmaker Atomo pops on ASX debut
Founder and CEO John Kelly speaks to AAP about the company’s ASX debut and the company’s unique position to make a major impact within the COVID-19 environment. The article was syndicated across a range of national, metropolitan and regional press, 7 News.com.au, 9Finance and Yahoo7...
16 Apr Stockhead: ASX newcomer Atomo Diagnostics breaks IPO drought; surges 125pc on debut
An article in Stockhead talks about how Atomo is focused on commercialising its rapid blood test devices for COVID-19. Read the full article here > ...
01 Apr Atomo secures significant European sales agreement and announces the early close of its oversubscribed $30 million Initial Public Offer
Atomo Diagnostics announced today that it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s integrated blood test devices to NG Biotech to use for its blood-based rapid test to detect COVID-19. Under the...
01 Apr MEDIA RELEASE: Atomo secures significant European sales agreement for rapid COVID-19 tests
$30m Initial Public Offer closes oversubscribed SYDNEY Australia, 01 April 2020: Australian rapid blood test company Atomo Diagnostics Limited (ACN 142 925 684) said today it has entered into a binding supply agreement with French diagnostics company, NG Biotech, SAS (NG Biotech), for the supply of Atomo’s...
- 1
- 2